Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Development of the 2023 ACR / EULAR Antiphospholipid Syndrome Classification Criteria, Phase III ‐C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions

Arthritis Care & Research(2025)10.1002/acr.25599Source: DataRank Database

Development of the 2023 ACR / EULAR Antiphospholipid Syndrome Classification Criteria, Phase III ‐C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions is a research paper published in Arthritis Care & Research (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.84)OA: bronzeTopics (32)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (31)

Stéphane Zuily ORCID,Deanna Jannat‐Khah ORCID,Mary‐Carmen Amigo ORCID,Danieli Andrade ORCID,Tadej Avčin ORCID

Live enrichment

PubMed:40621809 OpenAlex:https://openalex.org/W4412091567

Rheumatology Research Foundation

Grant: Investigator Award

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Grant: K24 AR066109

King's BHF Centre for Award Excellence

Grant: RE/18/2/34213

American College of Rheumatology

European Alliance of Associations for Rheumatology

American College of Rheumatology

European Alliance of Associations for Rheumatology

FWCI

0.84

Citation Percentile

0.7%

Citation Trend

2025

bronzeLicense: http://doi.wiley.com/10.1002/tdm_license_1.1

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acr.25599

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/acr.25599

publisherhttps://acrjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/acr.25599

publisherhttps://acrjournals.onlinelibrary.wiley.com/doi/full-xml/10.1002/acr.25599

journalhttps://doi.org/10.1002/acr.25599

Fields of Study

Systemic Lupus Erythematosus ResearchRheumatoid Arthritis Research and TherapiesVasculitis and related conditionsHumansAntiphospholipid SyndromeAntibodies, AntiphospholipidFemaleMaleAdultMiddle AgedRheumatologyRisk Factors

MeSH Terms

AdultFemaleHumansMaleMiddle AgedRheumatologyRisk FactorsAntiphospholipid SyndromeAntibodies, Antiphospholipid

Keywords

MedicineAntiphospholipid syndromeLupus anticoagulantConfidence intervalInternal medicinePoisson regressionRelative riskAntibodyCohortImmunologyPopulation

Sustainable Development Goals

SDG 0: Good health and well-being